Cargando…

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain

Acute pain, prevalent as part of postoperative and traumatic pain, is often sub-optimally or inadequately treated. Fixed-dose combination analgesic products that combine a reduced amount of opioid with a nonopioid analgesic such as acetaminophen (paracetamol) in a single tablet offer potential pharm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pergolizzi, Joseph V., Taylor, Robert, Raffa, Robert B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487354/ https://www.ncbi.nlm.nih.gov/pubmed/26026272 http://dx.doi.org/10.1007/s12325-015-0213-5

Ejemplares similares

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
por: Gudin, Jeff
Publicado: (2016)

Profile of extended-release oxycodone/acetaminophen for acute pain
por: Bekhit, Mary Hanna
Publicado: (2015)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature
por: Taylor, Robert, et al.
Publicado: (2012)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets
por: Franke, Ryan M, et al.
Publicado: (2015)

In response to Gudin et al. — Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties
por: Crudele, Nancy T., et al.
Publicado: (2017)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Prophylaxis of Postoperative Nausea and Vomiting in Adolescent Patients: A Review with Emphasis on Combination of Fixed-Dose Ondansetron and Transdermal Scopolamine
por: Pergolizzi, Joseph V., et al.
Publicado: (2011)

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2018)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
por: Markman, John, et al.
Publicado: (2018)

Response to Crudele et al. Commentary on Gudin et al. “Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties”
por: Gudin, Jeff, et al.
Publicado: (2017)

Designing Opioids That Deter Abuse
por: Raffa, Robert B., et al.
Publicado: (2012)

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain
por: Pergolizzi, Joseph V, et al.
Publicado: (2012)

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
por: Rossiter, Louis F, et al.
Publicado: (2020)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation
por: Webster, Lynn R, et al.
Publicado: (2019)

Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology
por: Darwish, Mona, et al.
Publicado: (2015)

A Guide for Pain Management in Low and Middle Income Communities. Managing the Risk of Opioid Abuse in Patients with Cancer Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2016)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

Tramadol/Paracetamol Fixed-Dose Combination for Chronic Pain Management in Family Practice: A Clinical Review
por: Morón Merchante, Ignacio, et al.
Publicado: (2013)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain
por: De Santis, Stefano, et al.
Publicado: (2021)

Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain
por: Hale, Martin E, et al.
Publicado: (2015)

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective
por: Ferrarese, Fabio, et al.
Publicado: (2008)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study
por: Nolte, Thomas, et al.
Publicado: (2013)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2017)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_093l6kr8jb4ihvsprtchv11m22